Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

26.53
+0.72002.79%
Post-market: 15.05-11.4800-43.27%19:59 EDT
Volume:7.17M
Turnover:139.68M
Market Cap:2.61B
PE:-4.55
High:26.80
Open:25.96
Low:25.57
Close:25.81
52wk High:39.89
52wk Low:18.29
Shares:98.32M
Float Shares:80.72M
Volume Ratio:4.36
T/O Rate:8.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-8.96
PE(LYR):-4.55

Loading ...

Feb 08, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 08, 2024

Major Issues Report

Form 8-K - Current report
Dec 29, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 22, 2023

Major Issues Report

Form 8-K - Current report
Nov 03, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 03, 2023

Major Issues Report

Form 8-K - Current report
Oct 24, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 23, 2023

Major Issues Report

Form 8-K - Current report
Oct 20, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Oct 19, 2023

[Supp]Public Prospectus

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
Oct 16, 2023

Major Issues Report

Form 8-K - Current report
Sep 12, 2023

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Sep 08, 2023

Major Issues Report

Form 8-K - Current report
Sep 07, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 05, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 04, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 03, 2023

Major Issues Report

Form 8-K - Current report
Jul 12, 2023

Major Issues Report

Form 8-K - Current report
Jul 06, 2023

Major Issues Report

Form 8-K - Current report
Jun 30, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities